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Abstract E-cadherin, a transmembrane adhesion molecule,
and phosphatase of regenerating liver 3 (PRL-3) protein, a
member of the family of tyrosine phosphatases, seem to be
responsible for cancer cell migration. Therefore, the study
objective was to determine a correlation between PRL-3 and
E-cadherin, to assess their expression in neoplastic tissue and
normal mucosa of the stomach, to analyze their effect on
cancer advancement, and to evaluate their potential as prog-
nostic markers in gastric cancer. The expressions of PRL-3
and E-cadherin were assessed immunohistochemically in 71
patients with gastric cancer. Positive expression of PRL-3 was
observed in 42.2 % of gastric cancer cases, whereas E-
cadherin expression was abnormal in 38% of cases. The study
revealed that the positive PRL-3 expression and abnormal E-
cadherin expression were associated with mucinous gastric
carcinoma and lymph node involvement. The former was also
related to the infiltrating type of tumor and abnormal E-
cadherin expression. The expression of PRL-3, but not of E-
cadherin, was associated with shorter survival of patients.
PRL-3 and E-cadherin exhibit interactions in gastric cancer
and are involved in the formation of lymph node metastases.
The PRL-3 protein can be an independent predictive factor of
overall survival in gastric cancer patients.
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Introduction
The phosphatase of regenerating liver 3 (PRL-3) protein be-
longs to the family of tyrosine phosphatases, with a unique
COOH-terminal prenylation motif, and it is thus involved in a
major reaction for the cell, i.e., dephosphorylation of tyrosine
residues deactivating enzymes. Although its physiological
role is poorly investigated, literature data suggest that PRL-3
takes part in neoformation, i.e., in migration, metastasizing,
and angiogenesis [1, 2]. However, factors that regulate PRL-3
expression as well as its enzymes are not well known, and
researchers are still searching for pathways and processes
associated with the protein involvement. A few studies have
revealed a link between PRL-3 and proteins responsible for
cytoskeleton rebuilding [3–7]. Regulation of cell adhesion is
another mechanism of the protein in the promotion of cancer
cell invasion and metastasizing [8, 9]. The PRL-3 is also
involved in tumor growth through the mechanism of
epithelial-mesenchymal transformation (EMT). PRL-3 acti-
vates the Akt pathway, which results in glycogen synthase
kinase 3β (GSK-3β) inactivation and then in overexpression
of mesenchymal markers—vimentin, fibronectin, and Snail—
and a decrease in γ-catenins, integrin β3, and E-cadherin
responsible for cell adhesion [10].
E-cadherin is a transmembrane protein, which, in normal
epithelium, is responsible for intracellular interactions. Its
cytoplasmic domain interacts with β-catenin or γ-catenin.
The complex that is formed binds α-catenin, which directly
affects the cytoskeleton [11, 12]. In cancers, dysfunction of E-
cadherin induced by lack of the cytoplasmic domain (no
interaction with catenins) or extracellular domain (no interac-
tion with adjacent cells with a simultaneous accumulation of
catenins) and changes in mutations are observed. These dis-
orders can lead to the detachment of cancer cells from the
primary tumor mass and thus increase their invasiveness [13,
14].
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Considering the similar role of both proteins in the migra-
tion of cancer cells and EMT, the objective of the current study
was to determine the correlation between the PRL-3 protein
and E-cadherin, to assess their expression in cancer tissue and
in normal gastric mucosa, as well as to investigate their effect
on tumor stage. Also, the prognostic potential of both proteins
was assessed in gastric cancer.
Material and methods
The study involved 71 patients with gastric cancer treated
surgically in the Second Department of General Surgery and
Gastroenterology in the years 2005–2010. As a control,
healthy gastric mucosa was collected from a stomach frag-
ment removed during therapeutic surgery. The postoperative
material was fixed in buffered and paraffin-embedded forma-
lin. From paraffin blocks, 4-μm sections were cut off and
stained with hematoxylin-eosin (H+E). Routine histopatho-
logical analysis included determination of tumor histological
type, malignancy grade (G), anatomoclinical stage (pT), and
lymph node metastases. Gastric cancers were also divided
according to Lauren’s classification [15], Goseki’s classifica-
tion [16], and Borrmann’s classification [17]. Also, the pres-
ence ofHelicobacter pylori infection was assessed in Giemsa-
stained preparations.
Immunohistochemical analysis Tissue blocks were cut using
a microtome into 4-μm-thick sections on silanized glasses.
The sections were deparaffinized in xylenes and hydrated in
alcohols. In order to exhibit antigen, the tissue sections were
heated in a microwave for 15 min in citrate buffer (pH=6.0).
Then, they were incubated with 0.5 % hydrogen peroxide in
methanol to block endogenous peroxidase and, next, with
mouse anti-PRL-3 antibody (clone 3B6; Attogen Biomedical
Research, USA; 1:500 dilution) overnight at 4 °C and with
mouse monoclonal anti-E-cadherin antibody (clone 36B5).
Following streptavidin-biotin reaction (biotinylated secondary
antibody, streptavidin-HRP; Novocastra, UK), the antigen-
antibody complex was visualized by application of chromo-
gen 3,3′-diaminobenzidine (DAB; Novocastra, UK). The ex-
pressions of the proteins were assessed using the semiquanti-
tative method, which defined PRL-3 expression as positive
when the reaction was visible in more than 5 % of cancer cells
and negative when there was no reaction or it was present in
<5 % of cells. For E-cadherin, the reaction was normal when
the membranous expression of the protein was present in
>30 % of cells; it was abnormal when negative or when
membranous expression was present in <30 % of cells or in
the case of cytoplasmic expression. Positive reaction was
calculated in at least 500 cancer cells in each tissue section
using a light microscope (×400).
The statistical analysis was based on Fisher’s test and χ2 test.
Log-rank test which is according to Kaplan-Meier survival
analysis approachwas employed to compare the overall survival
rate of patients. A Cox proportional hazard model was used for
univariate and multivariate analyses. A p value of <0.05 was
considered statistically significant. The statistics was performed
using STATISTICA 10 (Poland).
Results
PRL-3 and E-cadherin expression in normal gastric mucosa
and in gastric cancer
Normal gastric mucosa did not show PRL-3 expression,
whereas E-cadherin was present on the cytoplasmic mem-
brane of most glandular cells. The neoplastic tissue had a
positive expression of PRL-3 in 42.2 % (30/71) of gastric
cancer cases, whereas abnormal expression of E-cadherin was
observed in 38 % (27/71) of cases (Fig. 1).
PRL-3 and E-cadherin expression in correlation
to clinicopathological parameters in gastric cancer
Statistical analysis revealed no correlations of the expression
of PRL-3 and E-cadherin with sex, age, tumor location, infil-
tration depth (pT), malignancy grade, tumor type according to
Goseki and Lauren, and the presence of H. pylori infection.
The positive expression of PRL-3 and abnormal expression of
E-cadherin were shown to be associated with a mucinous type
of gastric cancer (p=0.002 and p=0.012, respectively). Posi-
tive expression of PRL-3 was also related with the infiltrating
type of tumor in Borrmann’s classification (p=0.037). Patients
with local lymph node involvement also had increased PRL-3
and abnormal E-cadherin expression in primary tumor
(p<0.001). Moreover, positive PRL expression was associat-
ed with abnormal expression of E-cadherin (p=0.007)
(Table 1).
Correlation of PRL-3 and E-cadherin expression
with patients’ survival
Overall assessment of patients’ survival showed a lack of
correlation between the expression of E-cadherin and survival
rate (p=0.510). However, the postoperative time of overall
survival in patients with positive PRL-3 expression was mark-
edly shorter (p=0.023) (Fig. 2).
Prognostic factors of gastric cancer
As shown by univariate Cox regression analysis, tumor loca-
tion, histological malignancy grade, tumor type in Lauren’s
classification, and positive PRL-3 expression were essential
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predictive factors of overall survival among gastric cancer
patients (p=0.046, 0.004, 0.021, and 0.002, respectively).
Malignancy grade, tumor type in Lauren’s classification, and
positive PRL-3 expression were independent predictive fac-
tors of overall survival for these patients (p=0.006, 0.011, and
0.001, respectively) (Table 2).
Discussion
EMT is a physiological process of growing embryos during
which epithelial cells are transformed into mesenchymal cells.
In a similar way, cancer cells of epithelial origin change into
mobile mesenchymal cells. Cell junctions are lost, and cancer
cells in this form are able to migrate to remote parts of the
body. After being released from the primary tumor, they
invade the surrounding tissues, penetrate lymphatic or blood
vessels, and migrate through the vascular wall, where they
eventually settle, proliferate, and induce angiogenesis. There,
they become transformed into epithelial cells and adhere
tightly to one another to form a metastatic tumor [18]. The
ability of cancer cells to disseminate from the primary tumor
to lymph nodes and to the nearest and distant tissues and
organs is a major feature of malignant neoplasms and the main
cause of therapeutic failure. Since tumor stage pTNM is the
key factor, with the greatest significance in the treatment of
gastric cancer patients, research into markers involved in
metastasizing has been intensified. E-cadherin, a transmem-
brane adhesion molecule and PRL-3 belonging to the family
of tyrosine phosphatases seem to be particularly responsible
for the migration of cancer cells. Wang et al. [19] have been
the first to suggest the involvement of PRL-3 in EMT. They
have put forward the hypothesis that PRL-3 activates the Akt
pathway through direct inhibition of PTEN (inhibitor for
PI3K), which results in GSK-3β inactivation. Next, Liu
et al. [20] have presented evidence for PRL-3 involvement
in EMT via cadherin-related signaling pathway. Most likely,
PRL-3 plays a major role in direct inhibition of the expression
Fig. 1 Immunohistochemical staining. a PRL-3 expression in the gastric
mucosa. b Positive cytoplasmic PRL-3 reaction in gastric cancer cells. c
Cytoplasmicmembrane expression of E-cadherin in the gastric mucosa. d
Negative of E-cadherin expression in gastric cancer cells. Original mag-
nification: ×200 and ×400
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of E-cadherin and CDH22 [20]. In our study, we analyzed the
immunohistochemical correlation between the expression of
PRL-3 and E-cadherin in gastric cancer and observed a cor-
relation between increased PRL-3 expression and abnormal E-
cadherin expression (p=0.007), which indicates that they may
interact.
We also compared the relationship of PRL-3 and E-
cadherin with clinicopathological parameters in gastric cancer.
Table 1 Relationship between
the expressions of PRL-3 and E-
cadherin proteins and clinico-
pathological parameters in gastric
cancer
Significant relationship is marked
in italics
Missing data were removed in
pairs
Variables PRL-3 expression p value E-cadherin expression p value
Absent Present Abnormal Normal
Age
≤50 10 10 0.415 12 12 0.358
>50 31 20 15 32
Gender
Male 28 21 0.880 21 30 0.591
Female 13 9 6 14
Location
Upper 1/3 2 4 0.114 1 1 0.568
Middle 1/3 16 14 14 16
Lower 1/3 23 12 13 26
Depth of invasion
T1 5 1 0.114 1 5 0.794
T2 11 6 6 8
T3 25 23 21 30
Histological differentiation
Moderately differentiated 20 9 0.115 12 23 0.585
Poorly differentiated 21 21 15 21
Hp
Adenocarcinoma 36 17 0.002 21 42 0.012
Adenocarcinoma mucinosum 5 13 10 5
Goseki’s classification
I 7 4 0.254 3 5 0.188
II 8 10 9 11
III 5 5 6 5
IV 14 18 17 13
Lauren’s classification
Intestinal type 31 16 0.051 16 35 0.086
Diffuse type 10 14 11 9
Borrmann’s classification
I (polypoid) 4 1 0.037 3 4 0.935
II (fungating) 8 4 8 13
III (ulcerated) 26 17 19 27
IV (infiltrative) 3 8 7 10
Lymph node metastasis
Absent 40 9 <0.001 10 45 <0.001
Present 1 21 17 1
Helicobacter pylori infection
Absent 16 18 0.373 15 20 0.320
Present 20 17 12 24
E-cadherin expression
Abnormal 9 14 0.007 – – –
Normal 28 10
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We revealed a correlation of positive PRL-3 and abnormal E-
cadherin with mucinous type of gastric cancer. Similar obser-
vations have been reported by other authors, indicating a
relationship between these proteins and signet ring cell-type
carcinoma [21, 22]. It is likely that an abnormal expression of
E-cadherin and an overexpression of PRL-3 are associated
with the loss of cell junctions and loosening of cells in this
histological type. Importantly, both proteins were found to
correlate with the presence of local lymph node metastases.
Thus, PRL-3 and E-cadherin seem to exert an extremely
significant effect on the spread of gastric cancer through the
lymphatic pathway. Our findings are compatible with earlier
literature data [21–24].
We also analyzed whether the proteins could be prognostic
factors in gastric cancer. Only the positive expression of PRL-
3 was found to correlate with shorter survival of patients. We
also demonstrated that PRL-3 was an independent prognostic
factor and could be used as a therapeutic target in this cancer.
Ooki et al. [24] have additionally observed that PRL-3 over-
expression is an independent prognostic factor in patients with
gastric cancer without metastases to local lymph nodes as
compared to patients with lymph node involvement. Although
other studies, including the research conducted by Li et al.
[25], have shown that also an abnormal expression of E-
cadherin can be a strong independent prognostic factor of
the overall survival of patients with gastric cancer, we did
not observe such correlations for the expression of E-
cadherin.
In conclusion, our study found a significant correlation
between PRL-3 protein and E-cadherin. However, it is the
Fig. 2 Postoperative overall survival of patients with gastric cancer. Comparison of postoperative survival according to the expressions of PRL-3 and E-
cadherin
Table 2 Univariate and multivariate analysis of clinicopathological factors in gastric cancer
Variables Univariate p value Multivariate p value Hazard ratio 95 % CI
Age (≤50 vs. >50) 0.081 – 1.600 0.942–2.715
Gender (male vs. female) 0.641 – 1.137 0.660–1.959
Location (upper 1/3, middle 1/3, vs. lower 1/3) 0.873 – 1.042 0.627–1.730
Depth of invasion (T1, T2, vs. T3) 0.046 0.078 1.852 1.008–3.403
Histological differentiation (moderately diff. vs. poorly diff.) 0.641 – 1.145 0.646–2.029
Hp (adc. vs. adc. mucinosum) 0.004 0.006 0.293 0.127–0.678
Goseki’s classification (I and III vs. II and IV) 0.864 – 1.073 0.476–2.419
Lauren’s classification (intestinal type vs. diffuse type) 0.021 0.011 2.422 1.140–5.143
Borrmann’s classification (I and II vs. III and IV) 0.068 – 0.587 0.331–1.040
Lymph node metastasis (absent vs. present) 0.372 – 0.705 0.327–1.519
Helicobacter pylori infection (absent vs. present) 0.713 – 1.109 0.635–1.937
PRL-3 expression (absent vs. present) 0.002 0.001 4.059 1.615–10.198
E-cadherin expression (abnormal vs. normal) 0.318 – 0.713 0.367–1.384
Significant relationship is marked in italics
Borrmann’s classification: I (polypoid), II (fungating), III (ulcerated), and IV (infiltrative)
diff. differentiated, adc. adenocarcinoma, CI confidence interval
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PRL-3 protein which seems to be more important in the
growth of gastric cancer.
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